Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07698548 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fuyang Jiedu Granules Plus Antiretroviral Therapy for HIV Immune Non-Responders With Spleen-Kidney Yang Deficiency

Study acronym: FYJD-INR-pRCT
StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This pragmatic randomized controlled trial evaluates whether Fuyang Jiedu Granules combined with antiretroviral therapy (ART) improves immune reconstitution in people with HIV who meet criteria for immune reconstitution failure and spleen-kidney yang deficiency syndrome. Eligible participants are adults aged 18 to 60 years with HIV-1 infection, long-term viral suppression on ART, and persistently low CD4+ T-cell counts. A total of 240 participants will be randomized 1:1 to receive Fuyang Jiedu Granules plus ART or ART alone. Treatment lasts 48 weeks, followed by 48 weeks of follow-up. The primary outcomes are absolute CD4+ T-cell count and immune reconstitution response rate. Secondary outcomes include immune homeostasis markers, T-cell activation and Treg proportion, thymic output and inflammation-related markers, HIV RNA viral load, quality of life, clinical symptom scores, all-cause mortality, and safety.
Trial Details
NCT Number NCT07698548
Lead Sponsor Beijing University of Chinese Medicine
Collaborators: Beijing YouAn Hospital, Capital Medical University, Chengdu Public Health Clinical Center, Chongqing Public Health Medical Center
Conditions
(from sponsor)		 HIV-1 Infection, Acquired Immunodeficiency Syndrome, Immune Reconstitution Failure, Immunological Non-responder, Spleen-Kidney Yang Deficiency Syndrome
Related terms Acquired Immunodeficiency Syndrome
Enrollment 240 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov